The aim of this study was to investigate the factors relating to CD4 level at HIV diagnosis and HIV testing behaviour. Participants were newly diagnosed patients (n = 654) in Japan from 2000 to 2005. Around 75% of participants were diagnosed at hospital and clinics. Mean CD4 counts at diagnosis through voluntary HIV testing, screening tests and testing due to concomitant sexually transmitted infection (STI) were 368, 336 and 316 cells/μL, respectively. In contrast, the mean CD4 count where testing was due to the presence of HIV-related clinical symptoms was 151 cells/μL (P < 0.0001). Compared with those diagnosed at their first HIV test, those who had undertaken multiple HIV tests prior to diagnosis showed CD4 counts that increased significantly (P < 0.0001) in relation to the number of tests undertaken: CD4 count at first test was 232 cells/μL, second test 346 cells/μL and third or additional tests 439 cells/μL. According to our results, HIV testing policy that promotes HIV testing in medical settings and among STI patients is needed to facilitate earlier HIV diagnosis in Japan.
PalellaFJ, DelaneyKM, MoormanAC, The HIV Outpatient Study Investigators: declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med1998;280:1497–503
2.
LohseN, HansenAE, PedersenG, Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med2007;146:87–95
3.
LewdenC, CheneG, MorlatP, HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr2007;46:72–77
4.
ChadbornTR, DelpechVC, SabinCA, SinkaK, EvansBG. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004). AIDS2006;20:2371–79
5.
Jensen-FangelS, PedersenL, PedersenC, Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS2004;18:89–97
6.
PinkertonSD, HoltgraveDR, GalletlyCL. Infections prevented by increasing HIV serostatus awareness in the United States, 2001 to 2004. J Acquir Immune Defic Syndr2008;47:354–7
7.
KleinD, HurleyLB, MerrillD, QuesenberryCPJr. Consortium for HIV/AIDS Interregional Research. Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr2003;32:143–52
8.
SchwarczS, HsuL, DilleyJW, LoebL, NelsonK, BoydS. Late diagnosis of HIV infection: trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS. J Acquir Immune Defic Syndr2006;43:491–4
9.
DelpierreC, Dray-SpiraR, CuzinL, the VESPA Study Group. Correlates of late HIV diagnosis: implications for testing policy. Int J STD AIDS2007;18:312–7
10.
BorghiV, GirardiE, BellelliS, Late presenters in an HIV surveillance system in Italy during the period 1992–2006. J Acquir Immune Defic Syndr2008;49:282–6
11.
WongKH, LeeSS, LowKH, WanWY. Temporal trend and factors associated with late HIV diagnosis in Hong Kong, a low HIV prevalence locality. AIDS Patient Care STDs2003;17:461–9
12.
Centers for Disease Control and Prevention (CDC). Advancing HIV prevention: new strategies for a changing epidemic – United States, 2003. MMWR Morb Mortal Wkly Rep2003;52:329–32
13.
Centers for Disease Control and Prevention (CDC). Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Rep2001;50(RR-19):1–57
14.
BransonBM, HandsfieldHH, LampeMA, Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep2006;55(RR-14):1–17
15.
WalenskyPP, LosinaE, Steger-CravenKA, FreedbergKA. Identifying undiagnosed human immunodeficiency virus: The yield of routine, voluntary inpatient testing. Arch Intern Med2002;162:887–92
16.
OutcaltDG, MickeyT, WeisbuchJ, JonesR. Integrating routine HIV testing into a public health STD clinic. Public Health Rep2006;121:175–80
17.
GuptaSB, DingleySD, LamagniTL, The national CD4 surveillance scheme for England and Wales. Commun Dis Public Health2001;4:27–32
18.
HoltgraveDR. Costs and consequences of the US centers for disease control and prevention's recommendations for opt-out HIV testing. PLoS Med2007;4:e194
19.
HashimotoS, KawadoM, MurakamiY, Numbers of people with HIV/AIDS reported and not reported to surveillance in Japan. J Epidemiol2004;14:182–6
20.
Centers for Disease Control and Prevention (CDC). Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years – United States, 2008. MMWR Recomm Rep2008;51(RR10):1–8
21.
Centers for Disease Control and Prevention (CDC). Late versus early testing of HIV-16 Sites, United States, 2000–2003. MMWR Morb Mortal Wkly Rep2003;52:581–6
22.
LyonsMS, LindsellCJ, HawkinsDA, Contributions to early HIV diagnosis among patients linked to care vary by testing venue. BMC Public Health2008;8:220
23.
GirardiE, AloisiMS, AriciC, for the ICoNA Behavioural Epidemiology Study Group. Delayed presentation and late testing for HIV: demographic and behavioral risk factors in a multicenter study in Italy. J Acquir Immune Defic Syndr2004;36:951–9
24.
The UK Collaborative Group for HIV and STI surveillance. Testing Times. HIV and other Sexually Transmitted infections in the United Kingdom: 2007. London: Health Protection Agency, Center for Infections. November 2007
25.
SullivanAK, CurtisH, SabinCA, JohnsonMA. Newly diagnosed HIV infections: review in UK and Ireland. BMJ2005;330:1302–2
26.
BumsF, MercerCH, MerceyD, SadiqST, CurranB, KellP. Factors that may increase HIV testing uptake in those who decline to test. Sex Transm Infect2004;80:247–250
